This pill may help curb 2.7 lakh HIV cases in India

The once-a-day pill, called pre-exposure prophylaxis, can reduce the risk of HIV acquisition by over 85 per cent when taken consistently. 

Published: 11th May 2019 08:16 PM  |   Last Updated: 11th May 2019 08:40 PM   |  A+A-

HIV AIDS

For representational purposes

By IANS

NEW DELHI: Paired with a biannual testing programme, a combination drug used to prevent HIV infection has the potential to improve average per-person survival by nearly one year and block more than 270,000 HIV transmissions in India over a period of 15 years, says a study.

The once-a-day pill, called pre-exposure prophylaxis (PrEP), can reduce the risk of HIV acquisition by over 85 per cent when taken consistently. 

The new study, published in the journal Clinical Infectious Diseases, suggests that making PrEP available to men who have sex with men (MSM) and people who inject drugs (PWID) in India may be a cost-effective way of curbing the epidemic in the country.

"We know PrEP helps stop the spread of infection; the question is whether it is a good use of limited resources? Our study shows that PrEP is a cost-effective strategy for both MSM and PWID in India. For these groups, especially in areas with high HIV incidence, PrEP is worth rolling out," says lead and corresponding author Pooyan Kazemian of the Massachusetts General Hospital (MGH) in the US.

Using a widely-published mathematical model to project clinical and economic outcomes of HIV disease, the authors compared various prevention and testing programmes - including annual or biannual HIV testing alone, as well as PrEP paired with HIV testing - that could help reduce HIV infection and therefore improve survival for these high-risk groups. 

Their findings suggest that PrEP would increase survival substantially by reducing infection risk, while more frequent HIV testing would provide little additional benefit. 

"While the World Health Organization recommends quarterly HIV testing for those on PrEP, our analysis identifies PrEP with semi-annual testing as the cost-effective HIV prevention strategy for MSM and PWID in India," said co-author Nagalingeswaran Kumarasamy of the Voluntary Health Services in Chennai.

However, the authors noted that a nationwide PrEP rollout would be quite costly. 

If nearly 60 per cent of MSM and PWID across India participated in the programme, it would increase HIV care expenditures by over $900 million over a five-year period, the study said.

"Our findings suggest that geographic areas of highest HIV incidence should be targeted first to reduce the budget required," said co-author Nomita Chandhiok of the Indian Council of Medical Research in New Delhi.

Stay up to date on all the latest Nation news with The New Indian Express App. Download now
(Get the news that matters from New Indian Express on WhatsApp. Click this link and hit 'Click to Subscribe'. Follow the instructions after that.)
TAGS
India HIV

Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp